Afișare rezultate
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 |
Singh Dave123, Boguş Maxim4, Moskalenko Valentyn5, Noi Autori |
3 Brovary multidisciplinary clinical hospital, 4 Timofei Moșneaga Republican Clinical Hospital, |
European Respiratory Journal |
Nr. / 2021 / ISSN 0903-1936 /ISSNe 1399-3003 |
Disponibil online 19 July, 2023. Descarcări-0. Vizualizări-188 |
1-1 of 1